Dr. Mitchell S. Felder, Halberd Corporation’s Chief Technical Officer stated, “Although we were successful earlier in conjugating solid gold nanoparticles with Halberd’s patent-pending monoclonal antibody, we found that the gold was not sufficiently reactive to the radiowaves to accomplish the efficient eradication of the disease antigen. Iron oxide nanoparticles are the ideal metal for this process. Unfortunately, we were unable to create a stable conjugation of the iron oxide with our patent-pending antibody. The gold-coated iron nanoparticle, by contrast, provides the combination of traits to satisfy both conditions:
1- Sufficiently reactive to radio waves and laser emissive energy, and
2- The ability to facilitate a stable conjugation.
Our patented extracorporeal approach to treatments is a necessary element to the eradication of disease through radiofrequency waves and laser emissive energy.”
William A. Hartman, Halberd’s Chairman, President & CEO, commented, “We commend the ingenuity and persistence of our team to seek a viable solution. We now have a road to success with the appropriate combination of metallic properties for the disease eradication process. This discovery was only possible with the careful study and testing by Dr. Qiang Chen of GreenBioAZ. With a suitable conjugation methodology achieved, we can now proceed with proof-of-concept testing at Youngstown State University (YSU) using E. coli as a first step. After successful completion of testing at YSU, pathogenic virus testing at a secure Level 3 laboratory will be conducted under the direct supervision of Dr. Chen and the GreenBioAZ team, at the Arizona State University facility.”
Read the original article on Halberd Corporation.